Incyte | Passifs Courants



Current Liabilities Changement Date
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Exelixis USD 403.77M 9.42M 2025-01
Gilead Sciences USD 12B 279M 2024-12
Incyte USD 1.64B 140.2M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
MacroGenics USD 59.31M 1.4M 2024-09
Merck USD 28.42B 1.17B 2024-12
Moderna USD 2.21B 5M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Incyte Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.